Company Description
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases.
The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease and medication non-adherence.
Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in clinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature and subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant for metabolic diseases in cats.
The company is headquartered in Alameda, California.
| Country | United States |
| Founded | 1998 |
| IPO Date | Nov 19, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 37 |
| CEO | Adam Mendelsohn |
Contact Details
Address: 1350 South Loop Road Alameda, California 94502 United States | |
| Phone | 415 506 8462 |
| Website | vivani.com |
Stock Details
| Ticker Symbol | VANI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001266806 |
| CUSIP Number | 92854B109 |
| ISIN Number | US92854B1098 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Dr. Adam Mendelsohn Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Truc Le M.B.A. | Chief Operations Officer |
| Dr. Lisa E. Porter M.D. | Chief Medical Officer |
| Anthony Edward Baldor | Chief Financial Officer |
| Donald Dwyer M.B.A. | Chief Business Officer and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 25, 2025 | 8-K | Current Report |
| Jun 17, 2025 | 8-K | Current Report |
| Jun 11, 2025 | 8-K | Current Report |
| May 29, 2025 | 8-K | Current Report |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | 8-K | Current Report |
| May 6, 2025 | DEFR14A | Filing |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |